Abstract
High-frequency repetitive transcranial magnetic stimulation (rTMS) of the primary motor cortex for neuropathic pain has been shown to be effective, according to systematic reviews and therapeutic guidelines. However, our large, rigorous, investigator-initiated, registration-directed clinical trial failed to show a positive primary outcome, and its subgroup analysis suggested that the analgesic effect varied according to the site of pain. The aim of this study was to investigate the differences in analgesic effects of rTMS for neuropathic pain between different pain sites by reviewing our previous clinical trials. We included three clinical trials in this mini meta-analysis: a multicenter randomized controlled trial at seven hospitals (N = 64), an investigator-initiated registration-directed clinical trial at three hospitals (N = 142), and an exploratory clinical trial examining different stimulation parameters (N = 22). The primary efficacy endpoint (change in pain scale) was extracted for each patient group with pain in the face, upper limb, or lower limb, and a meta-analysis of the efficacy of active rTMS against sham stimulation was performed. Standardized mean difference (SMD) with 95% confidence interval (CI) was calculated for pain change using a random-effects model. The analgesic effect of rTMS for upper limb pain was favorable (SMD = −0.45, 95% CI: −0.77 to −0.13). In contrast, rTMS did not produce significant pain relief on lower limb pain (SMD = 0.04, 95% CI: −0.33 to 0.41) or face (SMD = −0.24, 95% CI: −1.59 to 1.12). In conclusion, these findings suggest that rTMS provides analgesic effects in patients with neuropathic pain in the upper limb, but not in the lower limb or face, under the conditions of previous clinical trials. Owing to the main limitation of small number of studies included, many aspects should be clarified by further research and high-quality studies in these patients.
Introduction
Migita et al. (1995) reported the pain-relieving effects of repetitive transcranial magnetic stimulation (rTMS) in two patients with central neuropathic pain. Since then, rTMS has been developed as a promising, safe, and non-invasive brain stimulation treatment tool with fewer side effects for chronic pain that may benefit patients who do not respond to conventional pharmacological therapies. In the early 2000s, 10-Hz rTMS to the primary motor cortex (M1) was shown to be effective in patients with neuropathic pain (Lefaucheur et al., 2001a,b). Since then, many studies have been conducted to investigate the optimal parameters. M1 of the hand area contralateral to the painful side was stimulated regardless of the pain site in some previous studies (Lefaucheur et al., 2001a,b, 2008; Khedr et al., 2005, 2015; André-Obadia et al., 2006, 2008, 2011, 2021; Sun et al., 2019; Quesada et al., 2020). Lefaucheur et al. included patients with unilateral pain predominating at the hands because anatomically, the M1 of the hand area can be identified more reliably as the stimulation site than the face and lower limbs areas (Lefaucheur et al., 2001a, 2006a). Some other study groups restricted their inclusion criteria to predominantly upper limb pain patients with central post-stroke pain or complex regional pain syndrome, and they also showed that active TMS relieved pain more effectively compared with sham stimulation (Pleger et al., 2004; Picarelli et al., 2010; Ojala et al., 2021). In contrast, some studies have examined the effectiveness of rTMS in alleviating pain at different stimulation sites (Hirayama et al., 2006; Lefaucheur et al., 2006b; Jette et al., 2013; de Oliveira et al., 2014; Lindholm et al., 2015; Ayache et al., 2016; Nurmikko et al., 2016; André-Obadia et al., 2018; Galhardoni et al., 2019; Attal et al., 2021; Freigang et al., 2021; Ojala et al., 2021). We have reported that 5 Hz-rTMS to M1 relieved neuropathic pain, but that to the primary somatosensory cortex, premotor area, and supplementary motor area did not (Hirayama et al., 2006). Based on earlier promising results, we subsequently conducted a large, rigorous, multicenter, randomized, blinded, controlled, parallel trial involving 144 patients with neuropathic pain. The results showed that five daily sessions of rTMS over M1 with 500 pulses/session at 5 Hz did not achieve better pain relief than sham stimulation. However, the subgroup analysis suggested that the analgesic effect of rTMS for upper limb pain was superior to that of rTMS for lower limb pain (Hosomi et al., 2020). Similarly, another study reported that the efficacy of rTMS for upper limb pain tended to be higher than that for lower limb pain (Hosomi et al., 2013). Considering our previous studies, we hypothesized that the pain relief effects of rTMS might differ, depending on the pain site.
In some systematic reviews and therapeutic guidelines, high-frequency rTMS of the M1 for neuropathic pain has been shown to be effective (Jin et al., 2015; Cruccu et al., 2016; Singer et al., 2017; O’Connell et al., 2018; Aamir et al., 2020; Lefaucheur et al., 2020; Leung et al., 2020; Moisset et al., 2020; Shen et al., 2020; Yang and Chang, 2020; Attia et al., 2021; Knotkova et al., 2021; Zhang et al., 2021). Moreover, the effectiveness of high-frequency rTMS has also been reported in some types of painful conditions, such as various non-neuropathic pain (Galhardoni et al., 2015; Lan et al., 2017; Cardinal et al., 2019; Ferreira et al., 2019). In addition to reports on the efficacy of rTMS for a variety of pain-causing conditions, differences in the pain-relieving effects of rTMS have been investigated for a variety of factors, including stimulation location and frequency, number of stimulation pulses per session, and number of sessions. Although various factors that influence the pain-relieving effects of rTMS treatment have been investigated, evidence of the pain-relieving effects of rTMS by pain site is lacking. Therefore, the primary purpose of this study was to investigate the differences in analgesic effects of rTMS over M1 for neuropathic pain between different pain sites by reviewing our previous clinical trials.
Materials and Methods
Study Design, Studies Selection, and Data Source
This study was a meta-analysis based on the results of our previous studies, which aimed to investigate the pain-relieving effects of rTMS treatment by pain site. Meta-analyses must generally be performed according to a predetermined procedure, which is the preferred reporting item for systematic reviews and meta-analyses statements (Liberati et al., 2009; Rethlefsen et al., 2021). However, to the best of our knowledge, only two studies have examined the differences in the pain relief effects of high-frequency rTMS by pain site (Lefaucheur et al., 2004; Ayache et al., 2016). In these studies, the level of significance (P-value) is clearly provided, but the amount or rate of the decrease in pain intensity is not, and there is a lack of data available for meta-analysis by pain site. Therefore, we defined this study as a mini meta-analysis, because only our previous trials were extracted and analyzed. We extracted randomized controlled trials (RCTs) of rTMS using the figure-of-8 coil for neuropathic pain, conducted at Osaka University Hospital as the main study institution, because this was the first attempt to review the analgesic effects at different pain sites. We included three of our previous clinical trials in this meta-analysis (Hosomi et al., 2013, 2020; Mori et al., 2021b). Hosomi et al. (2013) conducted a randomized, double-blind, sham-controlled trial, from 2009 to 2011, at seven centers in Japan, to assess the efficacy and safety of 10 daily doses of rTMS in patients with neuropathic pain. A series of 10 daily 5-Hz rTMS (500 pulses/session) of M1 or sham stimulation was applied to each patient with a follow-up of 17 days. This study was divided into two groups: group A had an active rTMS period followed by a sham period, and group B had a sham period followed by an active rTMS period. Therefore, the two groups were analyzed separately in this analysis. From the data from Hosomi et al. (2013), we used the mean visual analog scale (VAS) decrease over 10 sessions for this analysis. This was calculated by subtracting the VAS value immediately before the intervention from the VAS value immediately after the intervention for each session and then averaging them. Second, in a trial by Hosomi et al. (2020), a randomized, patient- and assessor-blinded, sham-controlled, parallel trial was conducted from 2016 to 2017 at three centers to obtain regulatory approval in Japan. A series of five daily 5-Hz rTMS (500 pulses/session) of M1 or sham stimulation was applied to each patient with a follow-up of 4 weeks. We used the mean VAS decrease over five sessions for this analysis from the data of Hosomi et al. (2020). The mean decrease in VAS score was calculated using the procedure described by Hosomi et al. (2013). Finally, in a trial by Mori et al. (2021b), a randomized, single-blind, sham-controlled, crossover exploratory study was conducted from 2017 to 2018 at Osaka University Hospital to explore the optimal stimulus conditions for treating neuropathic pain. Four single sessions of M1-rTMS at different parameters (1, 5-Hz with 500 pulses per session; 2, 10-Hz with 500 pulses per session; 3, 10-Hz with 2000 pulses per session; and 4, sham stimulation) were conducted in random order. From the data of Mori et al. (2021b), we used VAS decrease, which was calculated by subtracting the VAS score immediately after the intervention from that immediately before the intervention for this analysis. Since Mori et al. (2021b) conducted a crossover study examining four different stimulation conditions, the results of the rTMS condition (10 Hz over M1 hand, 2000 pulses/session) that produced significantly more effective pain relief compared with the sham stimulation were extracted and integrated into the present study. These studies were approved by the institutional review boards, and written informed consent was obtained from all participants.
Data Synthesis and Analysis
Changes in pain scale (VAS scale: 0 = no pain to 100 = maximal pain) were extracted as a primary efficacy endpoint from each trial, and a mini meta-analysis of the efficacy of active rTMS against sham stimulation was performed. Next, the efficacy of rTMS was analyzed for each patient group with pain in the face and upper or lower limbs. The chi-squared test and I2 statistic were used to quantify the heterogeneity between the trials. Heterogeneity was considered significant when chi-squared P < 0.10, and the I2 statistic was used to evaluate the degree of heterogeneity. Substantial heterogeneity was considered to be present when I2 was >50%. In this analysis, a random-effects model was used regardless of heterogeneity, considering the small sample size (Cochrane Handbook for Systematic Reviews of Interventions, Version 6.1, 2020; Chapter 10. Analyzing data and undertaking meta-analyses1). Standardized mean difference (SMD) with 95% confidence interval (CI) was calculated for pain change using a random-effects model. This analysis was performed using the Cochrane Collaboration’s software program Review Manager (RevMan) version 5.4.1. software (Cochrane Collaboration, Oxford, United Kingdom).
Assessment of Resting Motor Threshold
The relationship between resting motor threshold (RMT) and pain site was examined in an investigator-initiated registration-directed clinical trial (Hosomi et al., 2020), in which RMT was recorded at M1 corresponding to the painful body part. The multicenter RCT (Hosomi et al., 2013) and the exploratory clinical trial (Mori et al., 2021b) were excluded from the RMT analysis because RMT was only partially recorded in the former, and RMT at M1 of the hand was recorded regardless of the pain site in the latter. The difference in RMT by pain site was analyzed using a one-way analysis of variance (ANOVA).
Results
A total of 228 patients from three clinical trials were included in the analysis (Table 1). In group A of Hosomi et al. (2013), a total of 28 patients were included (upper limb pain, n = 15; lower limb pain, n = 8; facial pain, n = 5). The etiologies of neuropathic pain were as follows: cerebral lesion in 21 patients, spinal lesion in 4, peripheral nerve injury in 1, phantom limb in 1, and root avulsion in 1 patient. In group B of Hosomi et al. (2013), a total of 35 patients were included (upper limb pain, n = 20; lower limb pain, n = 14; facial pain, n = 1). The etiologies of neuropathic pain were as follows: cerebral lesion, 30 patients; spinal lesion, 3 patients; and phantom limb, 2 patients. In Hosomi et al. (2020), 142 patients were included (upper limb pain, n = 67; lower limb pain, n = 59; facial pain, n = 16). The etiologies of neuropathic pain were as follows: cerebral lesion, 54 patients; postherpetic neuralgia, 12 patients; spinal lesion, 9 patients; root avulsion, 9 patients; complex regional pain syndrome, 4 patients; phantom limb, 2 patients; and other lesions, 52 patients. In Mori et al. (2021b), a total 22 patients were included (upper limb pain, n = 10; lower limb pain, n = 10; facial pain, n = 2). The etiologies of neuropathic pain were as follows: cerebral lesion in 15 patients, complex regional pain syndrome in 3, peripheral nerve injury in 2, spinal lesion in 1, and root avulsion in 1 patient.
TABLE 1
| Study | N | Pain origin (N) | Target of stimulation | Parameters and Dosage | Design/Study center | Stimulator/Coil | Sham condition |
| Hosomi et al., 2013 | 29 | Stroke (22), Spinal lesion (4), Phantom limb (1), Root avulsion (1), Peripheral nerve injury (1) | M1 contralateral to painful side | 5-Hz, 90%RMT, total 500 pulses/session (50 pulses × 10 train/session, 10 sessions, ITI = 50 s) | Cross-over RCT/7 centers | Magstim Rapid, Magstim Company, or AAA- 81077, Nihon Kohden Corp./figure-of-8 | Sham coil + simultaneous electrical stimulation to the scalp |
| Hosomi et al., 2013 | 35 | Stroke (30), Spinal lesion (3), Phantom limb (2), Root avulsion (0), Peripheral nerve injury (0) | |||||
| Hosomi et al., 2020 | Active: 72 | Stroke (31), Spinal lesion (2), Postherpetic neuralgia (6), Root avulsion (4), Phantom limb (2), CRPS (2), Other (25) | M1 contralateral to painful side | 5-Hz, 90%RMT, total 500 pulses/session (50 pulses × 10 train/session, 5 sessions, ITI = 50 s) | Parallel RCT/3 centers | TEN-P11, Teijin Pharma Limited/eccentric figure-of-8 | |
| Sham: 70 | Stroke (23), Spinal lesion (7), Postherpetic neuralgia (6), Root avulsion (5), Phantom limb (0), CRPS (2), Other (27) | Sham coil + simultaneous electrical stimulation to the scalp | |||||
| Mori et al., 2021b | 22 | Stroke (15), CRPS (3), Spinal lesion (1), Root avulsion (1), Peripheral nerve injury (2) | the M1 hand area contralateral to the painful side | 10-Hz, 90%RMT, total 2000 pulses/session (50 pulses × 40 train/session, 1 session, ITI = 25 s) | Cross-over RCT/single center | MagPro X100, MagVenture/figure-of-8 | Sham coil |
Characteristics of our previous rTMS studies using the figure-of-eight coil.
N, Numbers of subjects; RMT, Resting Motor Threshold; M1, Primary motor cortex; CRPS, Complex Regional Painful Syndrome; RCT, Randomized Controlled Trial; ITI, Inter-train Interval; sec, second.
The Hosomi et al. (2013) (treatment group A) study includes participants with an active rTMS period followed by a sham period, and the Hosomi et al. (2013) (treatment group B) study includes participants with a sham period followed by an active rTMS period.
Figure 1 shows the results of the mini meta-analysis for the entire population. Heterogeneity was moderate (Chi-squared = 7.30, P = 0.06, I2 = 59%), and the analysis of the pooled analgesic outcome showed that the effect size was not statistically significant −0.33 (95% CI, −0.70 to 0.04; P = 0.08). In the analysis of the group of upper limb pain, heterogeneity was low (Chi-squared = 0.50, P = 0.92, I2 = 0%), and the analysis of the pooled analgesic outcome showed a significant effect size of −0.45 (95% CI, −0.77 −−0.13; P < 0.01) (Figure 2). This suggests that rTMS for neuropathic pain in the upper limbs was effective in decreasing pain intensity. In the analysis of the groups of lower limb pain and facial pain, heterogeneity was low (Chi-squared = 3.12, P = 0.37, I2 = 4%) and moderate (Chi-squared = 3.67, P = 0.16, I2 = 46%), respectively. The effect size for pain change was 0.04 (95% CI, −0.33 to 0.41; P = 0.82) for lower limb pain and −0.24 (95% CI, −1.59 to 1.12; P = 0.73) for facial pain (Figures 3, 4). rTMS was unlikely to be effective for neuropathic pain in the lower limbs or faces. The funnel plots were symmetrical, suggesting that the publication bias was low.
FIGURE 1
FIGURE 2
FIGURE 3
FIGURE 4
According to Hosomi et al. (2020), the mean RMTs (SD) at M1 face, hand, and foot were 60.3% of the maximum stimulator output (19.0), 60.1% (19.1), and 81.2% (13.1), respectively. There was a significant difference in RMT by pain site (P < 0.01) (Figure 5).
FIGURE 5
Discussion
This study investigated the differences in analgesic effects of rTMS over the M1 using a figure-of-8 coil for neuropathic pain between pain sites. The findings from the three extracted clinical trials showed that rTMS for patients with neuropathic pain in the upper limb was particularly effective. Meanwhile, rTMS for patients with neuropathic pain in the lower limb and face was not confirmed to be effective.
Our main finding showed that high-frequency rTMS treatment using a figure-of-8 coil for neuropathic pain (N = 226) had a different effect on pain relief at the pain site. There have been many studies on the pain relief effects of rTMS for neuropathic pain, but to the best of our knowledge, there are few reports on the differences in pain relief effects by pain site (Lefaucheur et al., 2004; Ayache et al., 2016). Ayache et al. showed that pain intensity was significantly reduced after rTMS for both upper and lower limb pain (N = 20 and 16, respectively) (Ayache et al., 2016). Lefaucheur et al. showed that rTMS was more effective over the M1 hand area in facial pain (N = 14) than in upper and lower limb pain (N = 27 and 19, respectively) (Lefaucheur et al., 2004). The participants in these studies experienced a mixed condition of neuropathic pain, that is, central or peripheral neuropathic pain, similar to the participants in our three clinical trials. The stimulation condition set by Hosomi et al. (2013, 2020) was relatively low compared to those set by Lefaucheur et al. (2004) and Ayache et al. (2016) (5 Hz with 500 pulses/session vs. 10 Hz with 1,000 to 3,000 pulses/session). Mori et al. (2021b) adopted a high-dose (10 Hz with 2,000 pulses/session), but the results were not favorable for lower limb pain (SMD −0.04, 95% CI −0.91 to 0.84). The other difference was the manner of sham stimulation. In our previous trials, realistic sham stimulation, which produces scalp sensations and sounds similar to active stimulation without cortical stimulation, was performed by electrical stimulation and kept the conditions as similar as possible between active and sham stimulation. Consequently, realistic sham stimulation may have produced a large placebo effect. Although the manner of sham stimulation has differed between clinical trials, we do not think it is related to the difference in pain relief effect by pain site. Thus, the following comparison assessed the differences between the meta-analysis of the Cochrane review in single-session studies of high-frequency rTMS of M1 and this study. The SMD (95% CI) of pain score change in the Cochrane review (N = 249) was −0.38 (−0.49 to −0.27), and that for the whole population in this study was −0.33 (−0.70 to 0.04). Furthermore, the SMD (95% CI) for upper limbs pain in this study was −0.45 (−0.77 to −0.13). The SMDs (95% CI) of the two meta-analyses did not seem to be significantly different. Therefore, the results of the current study suggest that rTMS is clearly effective for upper limb pain and less effective for lower limb pain, as far as our previous studies are concerned.
We need to consider the factors that contribute to the difference in pain relief effects of rTMS for upper and lower limb pain. First, we showed that the RMT of the hand was clearly lower than that of the lower limb (Hosomi et al., 2013, 2020; Shimizu et al., 2017). Previous studies have demonstrated the correlation between RMT and the distance from the coil to the superficial layer of the brain (Stokes et al., 2005; Shimizu et al., 2017). Furthermore, previous studies in healthy subjects have reported that RMT was higher in the lower limb muscle (tibialis anterior) than that in the upper limb muscle (first dorsal interosseous), and it was higher in the figure-of-8 coil than that in the double-cone coil. The magnetic field strength produced by the double-cone coil is higher than that of the figure-of-8 coil (Schecklmann et al., 2020). This is due to the fact that the electric field generated by the figure-of-8 coil attenuates in relation to the depth of the target. Therefore, it is difficult to sufficiently stimulate the deep part of the brain with the figure-of-8 coil, especially the M1 foot area. To solve this problem of insufficient stimulation of the M1 foot area, rTMS with 3,000 pulses per session was performed under different stimulation conditions, such as stimulation intensity (90 or 110% RMT), coil position (M1 hand or foot area), and coil direction (anteroposterior or mediolateral) (Mori et al., 2021a). The results indicated that the analgesic effect was obtained in all conditions except sham stimulation, but simply increasing the intensity of the stimulation was not enough to eliminate pain. Second, the H-coil and double-cone coil, which can generate electric fields in the deep brain, have been used to stimulate the deep brain more effective than the figure-of-8 coil. One study investigated the analgesic effects of rTMS over the anterior cingulate cortex using an H-coil (Galhardoni et al., 2019). In addition, there are also reports that investigated the analgesic effect on foot pain with rTMS targeting the M1 foot using the H-coil (Onesti et al., 2013; Shimizu et al., 2017). In contrast, a pilot study of rTMS using a double-cone coil for chronic lower limb pain and a circular coil for upper limb pain failed to show significantly more effective pain relief compared with sham stimulation (Rollnik et al., 2002). According to a case report of invasive motor cortical stimulation, electrodes were implanted in the epidural area of the cortical regions corresponding to the painful area in patients with pain in the upper and lower limbs (Pommier et al., 2020). The stimulation of lower limb pain was inadvertently turned off and did not produce sufficient analgesic effect, but a turned-on stimulation reproduced sufficient pain relief. In addition, we implanted the subdural electrode over M1 corresponding to the painful site (Saitoh et al., 2000; Hosomi et al., 2008). Electrodes were implanted in the midline of the brain surface or in the interhemispheric fissure for lower limb pain (Hosomi et al., 2008). Presumably, another group used a similar technique to implant electrodes (Nguyen et al., 2011). These findings indicate the somatotopically driven analgesic efficacy of neuromodulation for lower limb pain. To alleviate pain with rTMS, it may be necessary to properly stimulate the target region. In the future, the efficacy of rTMS using an H-coil or double-cone coil for chronic pain needs to be further investigated.
In this meta-analysis, we focused on differences in the analgesic effects of rTMS over M1 at different pain sites. To date, some RCTs have been conducted in many centers to investigate various conditions. For example, trials have examined the pain-relieving effects of rTMS at different frequencies, different stimulation sites, and in single or multiple sessions, as well as trials examining the efficacy of rTMS for various neuropathic pain conditions, such as spinal cord injury (Yilmaz et al., 2014; Nardone et al., 2017; Sun et al., 2019), phantom limb pain (Ahmed et al., 2011; Malavera et al., 2016), traumatic brain injury (Choi et al., 2018), and radiculopathy (Attal et al., 2016). In recent years, some systematic reviews and meta-analyses have shown the efficacy and stimulation parameters of high-frequency rTMS for neuropathic pain (Baptista et al., 2019; Lefaucheur et al., 2020; Leung et al., 2020), and a practical algorithm for rTMS in the treatment of chronic pain in daily clinical practice has been proposed (Lefaucheur et al., 2020). In this algorithm, the stimulation site is not set to one specific area but to the M1 of the hand contralateral to the painful side or to the M1 corresponding to the painful area. If no improvement in pain is obtained, flexible parameters are proposed to change to a different stimulation site. Although this algorithm is a good clinically adapted setting, we consider that the optimal stimulation site to produce the analgesic effects of rTMS is controversial. Therefore, we reviewed RCTs of high-frequency rTMS in more than 10 patients with neuropathic pain (duration of more than 3 months) (Supplementary Table 1). We found that the M1 lower limb region was stimulated for lower limb pain in two studies using an H-coil (Onesti et al., 2013; Shimizu et al., 2017) and nine studies (Hirayama et al., 2006; Defrin et al., 2007; Saitoh et al., 2007; Kang et al., 2009; Hosomi et al., 2013, 2020; Jette et al., 2013; Ayache et al., 2016; Nurmikko et al., 2016) using a figure-of-8 coil. In contrast, the stimulation site in more than 10 studies targeted the M1 hand area, regardless of the pain site. A recent large RCT reported that rTMS over the M1 hand area was effective in patients with peripheral neuropathic pain. Approximately 60% of the participants were patients with lower limb pain (Attal et al., 2021). Previous studies have reported the efficacy of rTMS for peripheral neuropathic pain (Lefaucheur et al., 2004; Attal et al., 2016; Pei et al., 2019), and rTMS may be effective for peripheral neuropathic pain regardless of the pain site. However, considering the findings of previous studies, it is not clear whether targeting the somatotopic organization of M1 corresponding to painful areas can enhance pain relief. In the future, it will be necessary to investigate the optimal stimulation site according to the pain site and to select the optimal target population according to the stimulation site.
Our study has a few limitations. First, the main limitation of this study is the small sample size and the small number of studies included, which made the sensitivity analyses difficult. Second, as a methodological consideration of this analysis, the procedure of meta-analysis must be considered. Although a meta-analysis should be conducted according to a predetermined procedure (Liberati et al., 2009; Rethlefsen et al., 2021), we extracted and analyzed only three RCTs mainly conducted by Osaka University Hospital because there was little data to incorporate. Therefore, there was an obvious selection bias. The findings of this study suggest that a rigorous meta-analysis of the efficacy of rTMS by pain sites needs to be performed, and these findings need to be validated in the future. To achieve this, future prospective clinical trials should also provide site-specific pain results. Third, heterogeneity should be considered when interpreting the results of the meta-analysis. According to the Cochrane Handbook Version 6.2 see text footnote 1, caution should be taken when interpreting heterogeneity due to the poor power of the chi-squared test when the number of studies incorporated in the analysis is small. To compensate for the lack of power, the significance level of heterogeneity for the chi-squared test was set at 0.10 rather than the conventional level of 0.05. In this study, no heterogeneity was identified in the results for upper and lower limb pain, which was the main focus of this study. However, we found moderate heterogeneity in the results of the entire population and facial pain. As far as we could check, through visual inspection of the funnel plots of our previous studies incorporated in these analyses, it does not seem to be a non-specific asymmetry. We believe that the heterogeneity was significant for facial pain (N = 16) because the number of patients was too small compared to the analysis of upper limb pain (N = 76) and lower limb pain (N = 65). Because this study has been analyzed with a small number of patients, with only our previously generated results, it is necessary to take sufficient care while interpreting these results.
Conclusion
In conclusion, this study suggests differences in the analgesic effects of high-frequency rTMS over the M1 using the figure-of-8 coil for neuropathic pain between pain sites. More importantly, rTMS for upper limb pain was clearly effective in relieving pain. Meanwhile, rTMS for lower limb pain and facial pain did not produce an analgesic effect under the conditions of previous clinical trials. However, considering the small number of included studies, our findings should be considered tentative.
Publisher’s Note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Statements
Data availability statement
The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.
Ethics statement
The studies involving human participants were reviewed and approved by the Ethics Committee of Osaka University Hospital. Written informed consent to participate in this study was provided by the participants’ legal guardian/next of kin.
Author contributions
KH and NM contributed to trial design and conducted experiments and data collection. YS, SO, and HK supervised the study. All authors contributed to the data interpretation. NM drafted the manuscript. KH edited the manuscript. NM and KH conducted statistical analyses. All authors reviewed and approved the final manuscript.
Funding
This study was partly supported by the Japan Agency for Medical Research and Development (AMED) under grant nos. JP17hk0102029, JP19ek0610016, JP19dm0307007, and JP19dm0307008, and the Japan Society for the Promotion of Science (JSPS) KAKENHI under grant nos. JP17K10893, JP18K08993, and JP19K19867.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Supplementary material
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fnhum.2021.786225/full#supplementary-material
References
1
AamirA.GirachA.SarrigiannisP. G.HadjivassiliouM.PaladiniA.VarrassiG.et al (2020). Repetitive magnetic stimulation for the management of peripheral neuropathic pain: a systematic review.Adv. Ther.37998–1012. 10.1007/s12325-020-01231-2
2
AhmedM. A.MohamedS. A.SayedD. (2011). Long-term antalgic effects of repetitive transcranial magnetic stimulation of motor cortex and serum beta-endorphin in patients with phantom pain.Neurol. Res.33953–958. 10.1179/1743132811Y.0000000045
3
André-ObadiaN.MagninM.Garcia-LarreaL. (2011). On the importance of placebo timing in rTMS studies for pain relief.Pain1521233–1237. 10.1016/j.pain.2010.12.027
4
André-ObadiaN.MagninM.Garcia-LarreaL. (2021). Theta-burst versus 20 Hz repetitive transcranial magnetic stimulation in neuropathic pain: a head-to-head comparison.Clin. Neurophysiol.1322702–2710. 10.1016/j.clinph.2021.05.022
5
André-ObadiaN.MagninM.SimonE.Garcia-LarreaL. (2018). Somatotopic effects of rTMS in neuropathic pain? A comparison between stimulation over hand and face motor areas.Eur. J. Pain22707–715. 10.1002/ejp.1156
6
André-ObadiaN.MertensP.GueguenA.PeyronR.Garcia-LarreaL. (2008). Pain relief by rTMS: differential effect of current flow but no specific action on pain subtypes.Neurology71833–840. 10.1212/01.wnl.0000325481.61471.f0
7
André-ObadiaN.PeyronR.MertensP.MauguiereF.LaurentB.Garcia-LarreaL. (2006). Transcranial magnetic stimulation for pain control. Double-blind study of different frequencies against placebo, and correlation with motor cortex stimulation efficacy.Clin. Neurophysiol.1171536–1544. 10.1016/j.clinph.2006.03.025
8
AttalN.AyacheS. S.Ciampi De AndradeD.MhallaA.BaudicS.JazatF.et al (2016). Repetitive transcranial magnetic stimulation and transcranial direct-current stimulation in neuropathic pain due to radiculopathy: a randomized sham-controlled comparative study.Pain1571224–1231. 10.1097/j.pain.0000000000000510
9
AttalN.Poindessous-JazatF.De ChauvignyE.QuesadaC.MhallaA.AyacheS. S.et al (2021). Repetitive transcranial magnetic stimulation for neuropathic pain: a randomized multicentre sham-controlled trial.Brain10.1093/brain/awab208[Epub Online ahead of print].
10
AttiaM.McCarthyD.AbdelghaniM. (2021). Repetitive transcranial magnetic stimulation for treating chronic neuropathic pain: a systematic review.Curr. Pain Headache Rep.25:48. 10.1007/s11916-021-00960-5
11
AyacheS. S.AhdabR.ChalahM. A.FarhatW. H.MyliusV.GoujonC.et al (2016). Analgesic effects of navigated motor cortex rTMS in patients with chronic neuropathic pain.Eur. J. Pain201413–1422. 10.1002/ejp.864
12
BaptistaA. F.FernandesA.SaK. N.OkanoA. H.BrunoniA. R.Lara-SolaresA.et al (2019). Latin American and Caribbean consensus on noninvasive central nervous system neuromodulation for chronic pain management (LAC2-NIN-CP).Pain Rep.4:e692. 10.1097/PR9.0000000000000692
13
CardinalT. M.AntunesL. C.BrietzkeA. P.ParizottiC. S.CarvalhoF.De SouzaA.et al (2019). Differential neuroplastic changes in fibromyalgia and depression indexed by up-regulation of motor cortex inhibition and disinhibition of the descending pain system: an exploratory study.Front. Hum. Neurosci.13:138. 10.3389/fnhum.2019.00138
14
ChoiG. S.KwakS. G.LeeH. D.ChangM. C. (2018). Effect of high-frequency repetitive transcranial magnetic stimulation on chronic central pain after mild traumatic brain injury: a pilot study.J. Rehabil. Med.50246–252. 10.2340/16501977-2321
15
CruccuG.Garcia-LarreaL.HanssonP.KeindlM.LefaucheurJ. P.PaulusW.et al (2016). EAN guidelines on central neurostimulation therapy in chronic pain conditions.Eur. J. Neurol.231489–1499. 10.1111/ene.13103
16
de OliveiraR. A.de AndradeD. C.MendoncaM.BarrosR.LuvisotoT.MyczkowskiM. L.et al (2014). Repetitive transcranial magnetic stimulation of the left premotor/dorsolateral prefrontal cortex does not have analgesic effect on central poststroke pain.J. Pain151271–1281. 10.1016/j.jpain.2014.09.009
17
DefrinR.GrunhausL.ZamirD.ZeiligG. (2007). The effect of a series of repetitive transcranial magnetic stimulations of the motor cortex on central pain after spinal cord injury.Arch. Phys. Med. Rehabil.881574–1580. 10.1016/j.apmr.2007.07.025
18
FerreiraN. R.JunqueiraY. N.CorreaN. B.FonsecaE. O.BritoN. B. M.MenezesT. A.et al (2019). The efficacy of transcranial direct current stimulation and transcranial magnetic stimulation for chronic orofacial pain: a systematic review.PLoS One14:e0221110. 10.1371/journal.pone.0221110
19
FreigangS.LehnerC.FresnozaS. M.Mahdy AliK.HlavkaE.EitlerA.et al (2021). Comparing the impact of multi-session left dorsolateral prefrontal and primary motor cortex neuronavigated repetitive transcranial magnetic stimulation (nrTMS) on chronic pain patients.Brain Sci.11:961. 10.3390/brainsci11080961
20
GalhardoniR.Aparecida da SilvaV.Garcia-LarreaL.DaleC.BaptistaA. F.BarbosaL. M.et al (2019). Insular and anterior cingulate cortex deep stimulation for central neuropathic pain: disassembling the percept of pain.Neurology92e2165–e2175. 10.1212/WNL.0000000000007396
21
GalhardoniR.CorreiaG. S.AraujoH.YengL. T.FernandesD. T.KaziyamaH. H.et al (2015). Repetitive transcranial magnetic stimulation in chronic pain: a review of the literature.Arch. Phys. Med. Rehabil.96S156–S172. 10.1016/j.apmr.2014.11.010
22
HirayamaA.SaitohY.KishimaH.ShimokawaT.OshinoS.HirataM.et al (2006). Reduction of intractable deafferentation pain by navigation-guided repetitive transcranial magnetic stimulation of the primary motor cortex.Pain12222–27. 10.1016/j.pain.2005.12.001
23
HosomiK.SaitohY.KishimaH.OshinoS.HirataM.TaniN.et al (2008). Electrical stimulation of primary motor cortex within the central sulcus for intractable neuropathic pain.Clin. Neurophysiol.119993–1001. 10.1016/j.clinph.2007.12.022
24
HosomiK.ShimokawaT.IkomaK.NakamuraY.SugiyamaK.UgawaY.et al (2013). Daily repetitive transcranial magnetic stimulation of primary motor cortex for neuropathic pain: a randomized, multicenter, double-blind, crossover, sham-controlled trial.Pain1541065–1072. 10.1016/j.pain.2013.03.016
25
HosomiK.SugiyamaK.NakamuraY.ShimokawaT.OshinoS.GotoY.et al (2020). A randomized controlled trial of 5 daily sessions and continuous trial of 4 weekly sessions of repetitive transcranial magnetic stimulation for neuropathic pain.Pain161351–360. 10.1097/j.pain.0000000000001712
26
JetteF.CoteI.MezianeH. B.MercierC. (2013). Effect of single-session repetitive transcranial magnetic stimulation applied over the hand versus leg motor area on pain after spinal cord injury.Neurorehabil. Neural. Repair27636–643. 10.1177/1545968313484810
27
JinY.XingG.LiG.WangA.FengS.TangQ.et al (2015). High frequency repetitive transcranial magnetic stimulation therapy for chronic neuropathic pain: a Meta-analysis.Pain. Physician.18E1029–E1046.
28
KangB. S.ShinH. I.BangM. S. (2009). Effect of repetitive transcranial magnetic stimulation over the hand motor cortical area on central pain after spinal cord injury.Arch. Phys. Med. Rehabil.901766–1771. 10.1016/j.apmr.2009.04.008
29
KhedrE. M.KotbH.KamelN. F.AhmedM. A.SadekR.RothwellJ. C. (2005). Longlasting antalgic effects of daily sessions of repetitive transcranial magnetic stimulation in central and peripheral neuropathic pain.J. Neurol. Neurosurg. Psychiatry76833–838. 10.1136/jnnp.2004.055806
30
KhedrE. M.KotbH. I.MostafaM. G.MohamadM. F.AmrS. A.AhmedM. A.et al (2015). Repetitive transcranial magnetic stimulation in neuropathic pain secondary to malignancy: a randomized clinical trial.Eur. J. Pain19519–527. 10.1002/ejp.576
31
KnotkovaH.HamaniC.SivanesanE.Le BeuffeM. F. E.MoonJ. Y.CohenS. P.et al (2021). Neuromodulation for chronic pain.Lancet3972111–2124. 10.1016/S0140-6736(21)00794-7
32
LanL.ZhangX.LiX.RongX.PengY. (2017). The efficacy of transcranial magnetic stimulation on migraine: a meta-analysis of randomized controlled trails.J. Headache Pain18:86. 10.1186/s10194-017-0792-4
33
LefaucheurJ. P.AlemanA.BaekenC.BenningerD. H.BrunelinJ.Di LazzaroV.et al (2020). Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS): an update (2014-2018).Clin. Neurophysiol.131474–528. 10.1016/j.clinph.2019.11.002
34
LefaucheurJ. P.DrouotX.KeravelY.NguyenJ. P. (2001a). Pain relief induced by repetitive transcranial magnetic stimulation of precentral cortex.Neuroreport122963–2965. 10.1097/00001756-200109170-00041
35
LefaucheurJ. P.DrouotX.NguyenJ. P. (2001b). Interventional neurophysiology for pain control: duration of pain relief following repetitive transcranial magnetic stimulation of the motor cortex.Neurophysiol. Clin.31247–252. 10.1016/s0987-7053(01)00260-x
36
LefaucheurJ. P.DrouotX.Menard-LefaucheurI.KeravelY.NguyenJ. P. (2006a). Motor cortex rTMS restores defective intracortical inhibition in chronic neuropathic pain.Neurology671568–1574. 10.1212/01.wnl.0000242731.10074.3c
37
LefaucheurJ. P.HatemS.NinebA.Menard-LefaucheurI.WendlingS.KeravelY.et al (2006b). Somatotopic organization of the analgesic effects of motor cortex rTMS in neuropathic pain.Neurology671998–2004. 10.1212/01.wnl.0000247138.85330.88
38
LefaucheurJ. P.DrouotX.Menard-LefaucheurI.KeravelY.NguyenJ. P. (2008). Motor cortex rTMS in chronic neuropathic pain: pain relief is associated with thermal sensory perception improvement.J. Neurol. Neurosurg. Psychiatry791044–1049. 10.1136/jnnp.2007.135327
39
LefaucheurJ. P.DrouotX.Menard-LefaucheurI.ZerahF.BendibB.CesaroP.et al (2004). Neurogenic pain relief by repetitive transcranial magnetic cortical stimulation depends on the origin and the site of pain.J. Neurol. Neurosurg. Psychiatry75612–616. 10.1136/jnnp.2003.022236
40
LeungA.ShirvalkarP.ChenR.KuluvaJ.VaninettiM.BermudesR.et al (2020). Transcranial magnetic stimulation for pain, headache, and comorbid depression: INS-NANS expert consensus panel review and recommendation.Neuromodulation23267–290. 10.1111/ner.13094
41
LiberatiA.AltmanD. G.TetzlaffJ.MulrowC.GotzscheP. C.IoannidisJ. P.et al (2009). The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration.PLoS Med.6:e1000100. 10.1371/journal.pmed.1000100
42
LindholmP.LamusuoS.TaiminenT.PesonenU.LahtiA.VirtanenA.et al (2015). Right secondary somatosensory cortex-a promising novel target for the treatment of drug-resistant neuropathic orofacial pain with repetitive transcranial magnetic stimulation.Pain1561276–1283. 10.1097/j.pain.0000000000000175
43
MalaveraA.SilvaF. A.FregniF.CarrilloS.GarciaR. G. (2016). Repetitive Transcranial magnetic stimulation for phantom limb pain in land mine victims: a double-blinded, randomized, sham-controlled trial.J. Pain17911–918. 10.1016/j.jpain.2016.05.003
44
MigitaK.UozumiT.AritaK.MondenS. (1995). Transcranial magnetic coil stimulation of motor cortex in patients with central pain.Neurosurgery361037–1039. 10.1227/00006123-199505000-00025
45
MoissetX.BouhassiraD.Avez CouturierJ.AlchaarH.ConradiS.DelmotteM. H.et al (2020). Pharmacological and non-pharmacological treatments for neuropathic pain: systematic review and French recommendations.Rev. Neurol. (Paris)176325–352. 10.1016/j.neurol.2020.01.361
46
MoriN.HosomiK.NishiA.OshinoS.KishimaH.SaitohY. (2021b). Analgesic effects of repetitive transcranial magnetic stimulation at different stimulus parameters for neuropathic pain: a randomized study.Neuromodulation10.1111/ner.13328[Epub Online ahead of print].
47
MoriN.HosomiK.NishiA.MatsugiA.DongD.OshinoS.et al (2021a). An exploratory study of optimal parameters of repetitive transcranial magnetic stimulation for neuropathic pain in the lower extremities.Pain Rep.6:e964.
48
NardoneR.HollerY.LangthalerP. B.LochnerP.GolaszewskiS.SchwenkerK.et al (2017). rTMS of the prefrontal cortex has analgesic effects on neuropathic pain in subjects with spinal cord injury.Spinal Cord.5520–25. 10.1038/sc.2016.87
49
NguyenJ. P.NizardJ.KeravelY.LefaucheurJ. P. (2011). Invasive brain stimulation for the treatment of neuropathic pain.Nat. Rev. Neurol.7699–709. 10.1038/nrneurol.2011.138
50
NurmikkoT.MacIverK.BresnahanR.HirdE.NelsonA.SaccoP. (2016). Motor cortex reorganization and repetitive transcranial magnetic stimulation for pain-a methodological study.Neuromodulation19669–678. 10.1111/ner.12444
51
O’ConnellN. E.MarstonL.SpencerS.DeSouzaL. H.WandB. M. (2018). Non-invasive brain stimulation techniques for chronic pain.Cochrane Database. Syst. Rev.4:CD008208. 10.1002/14651858.CD008208.pub5
52
OjalaJ.VanhanenJ.HarnoH.LioumisP.VaaltoS.KaunistoM. A.et al (2021). A randomized, sham-controlled trial of repetitive transcranial magnetic stimulation targeting m1 and s2 in central poststroke pain: a pilot trial.Neuromodulation10.1111/ner.13496[Epub Online ahead of print].
53
OnestiE.GabrieleM.CambieriC.CeccantiM.RaccahR.Di StefanoG.et al (2013). H-coil repetitive transcranial magnetic stimulation for pain relief in patients with diabetic neuropathy.Eur. J. Pain171347–1356. 10.1002/j.1532-2149.2013.00320.x
54
PeiQ.WuB.TangY.YangX.SongL.WangN.et al (2019). Repetitive Transcranial magnetic stimulation at different frequencies for postherpetic neuralgia: a double-blind, sham-controlled, randomized trial.Pain Physician22E303–E313.
55
PicarelliH.TeixeiraM. J.de AndradeD. C.MyczkowskiM. L.LuvisottoT. B.YengL. T.et al (2010). Repetitive transcranial magnetic stimulation is efficacious as an add-on to pharmacological therapy in complex regional pain syndrome (CRPS) type I.J. Pain111203–1210. 10.1016/j.jpain.2010.02.006
56
PlegerB.JanssenF.SchwenkreisP.VolkerB.MaierC.TegenthoffM. (2004). Repetitive transcranial magnetic stimulation of the motor cortex attenuates pain perception in complex regional pain syndrome type I.Neurosci. Lett.35687–90. 10.1016/j.neulet.2003.11.037
57
PommierB.QuesadaC.NutiC.PeyronR.VassalF. (2020). Is the analgesic effect of motor cortex stimulation somatotopically driven or not?Neurophysiol. Clin.50195–203. 10.1016/j.neucli.2020.04.002
58
QuesadaC.PommierB.FauchonC.BradleyC.Creac’hC.MuratM.et al (2020). New procedure of high-frequency repetitive transcranial magnetic stimulation for central neuropathic pain: a placebo-controlled randomized crossover study.Pain161718–728. 10.1097/j.pain.0000000000001760
59
RethlefsenM. L.KirtleyS.WaffenschmidtS.AyalaA. P.MoherD.PageM. J.et al (2021). PRISMA-S: an extension to the PRISMA Statement for Reporting Literature Searches in Systematic Reviews.Syst. Rev.10:39. 10.1186/s13643-020-01542-z
60
RollnikJ. D.WustefeldS.DauperJ.KarstM.FinkM.KossevA.et al (2002). Repetitive transcranial magnetic stimulation for the treatment of chronic pain - a pilot study.Eur. Neurol.486–10. 10.1159/000064950
61
SaitohY.HirayamaA.KishimaH.ShimokawaT.OshinoS.HirataM.et al (2007). Reduction of intractable deafferentation pain due to spinal cord or peripheral lesion by high-frequency repetitive transcranial magnetic stimulation of the primary motor cortex.J. Neurosurg.107555–559. 10.3171/JNS-07/09/0555
62
SaitohY.ShibataM.HiranoS.HirataM.MashimoT.YoshimineT. (2000). Motor cortex stimulation for central and peripheral deafferentation pain. Report of eight cases.J. Neurosurg.92150–155. 10.3171/jns.2000.92.1.0150
63
SchecklmannM.SchmausserM.KlingerF.KreuzerP. M.KrenkelL.LangguthB. (2020). Resting motor threshold and magnetic field output of the figure-of-8 and the double-cone coil.Sci. Rep.10:1644. 10.1038/s41598-020-58034-2
64
ShenZ.LiZ.KeJ.HeC.LiuZ.ZhangD.et al (2020). Effect of non-invasive brain stimulation on neuropathic pain following spinal cord injury: a systematic review and meta-analysis.Medicine (Baltimore)99:e21507. 10.1097/MD.0000000000021507
65
ShimizuT.HosomiK.MaruoT.GotoY.YokoeM.KageyamaY.et al (2017). Efficacy of deep rTMS for neuropathic pain in the lower limb: a randomized, double-blind crossover trial of an H-coil and figure-8 coil.J. Neurosurg.1271172–1180. 10.3171/2016.9.JNS16815
66
SingerJ.ConigliaroA.SpinaE.LawS. W.LevineS. R. (2017). Central poststroke pain: a systematic review.Int. J. Stroke12343–355. 10.1177/1747493017701149
67
StokesM. G.ChambersC. D.GouldI. C.HendersonT. R.JankoN. E.AllenN. B.et al (2005). Simple metric for scaling motor threshold based on scalp-cortex distance: application to studies using transcranial magnetic stimulation.J. Neurophysiol.944520–4527. 10.1152/jn.00067.2005
68
SunX.LongH.ZhaoC.DuanQ.ZhuH.ChenC.et al (2019). Analgesia-enhancing effects of repetitive transcranial magnetic stimulation on neuropathic pain after spinal cord injury:An fNIRS study.Restor. Neurol. Neurosci.37497–507. 10.3233/RNN-190934
69
YangS.ChangM. C. (2020). Effect of repetitive transcranial magnetic stimulation on pain management: a systematic narrative review.Front. Neurol.11:114. 10.3389/fneur.2020.00114
70
YilmazB.KesikburunS.YasarE.TanA. K. (2014). The effect of repetitive transcranial magnetic stimulation on refractory neuropathic pain in spinal cord injury.J. Spinal Cord Med.37397–400. 10.1179/2045772313Y.0000000172
71
ZhangK. L.YuanH.WuF. F.PuX. Y.LiuB. Z.LiZ.et al (2021). Analgesic effect of noninvasive brain stimulation for neuropathic pain patients: a systematic review.Pain Ther.10315–332. 10.1007/s40122-021-00252-1
Summary
Keywords
repetitive transcranial magnetic stimulation (rTMS), motor cortex stimulation, neuropathic pain, meta-analysis, pain sites, upper limb, lower limb
Citation
Mori N, Hosomi K, Nishi A, Dong D, Yanagisawa T, Khoo HM, Tani N, Oshino S, Saitoh Y and Kishima H (2021) Difference in Analgesic Effects of Repetitive Transcranial Magnetic Stimulation According to the Site of Pain. Front. Hum. Neurosci. 15:786225. doi: 10.3389/fnhum.2021.786225
Received
29 September 2021
Accepted
29 October 2021
Published
26 November 2021
Volume
15 - 2021
Edited by
Masaki Sekino, The University of Tokyo, Japan
Reviewed by
Carmen Terranova, University of Messina, Italy; Enrica Laura Santarcangelo, University of Pisa, Italy
Updates
Copyright
© 2021 Mori, Hosomi, Nishi, Dong, Yanagisawa, Khoo, Tani, Oshino, Saitoh and Kishima.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Koichi Hosomi, k-hosomi@nsurg.med.osaka-u.ac.jp
This article was submitted to Brain Imaging and Stimulation, a section of the journal Frontiers in Human Neuroscience
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.